CLDX
Price
$20.35
Change
+$0.40 (+2.01%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
1.35B
76 days until earnings call
DNLI
Price
$13.42
Change
-$0.24 (-1.76%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
1.98B
69 days until earnings call
Interact to see
Advertisement

CLDX vs DNLI

Header iconCLDX vs DNLI Comparison
Open Charts CLDX vs DNLIBanner chart's image
Celldex Therapeutics
Price$20.35
Change+$0.40 (+2.01%)
Volume$12.92K
Capitalization1.35B
Denali Therapeutics
Price$13.42
Change-$0.24 (-1.76%)
Volume$17.95K
Capitalization1.98B
CLDX vs DNLI Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. DNLI commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Buy and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (CLDX: $19.95 vs. DNLI: $13.66)
Brand notoriety: CLDX and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 0% vs. DNLI: 73%
Market capitalization -- CLDX: $1.35B vs. DNLI: $1.98B
CLDX [@Biotechnology] is valued at $1.35B. DNLI’s [@Biotechnology] market capitalization is $1.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 3 bullish TA indicator(s).

  • CLDX’s TA Score: 6 bullish, 3 bearish.
  • DNLI’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than DNLI.

Price Growth

CLDX (@Biotechnology) experienced а -0.75% price change this week, while DNLI (@Biotechnology) price change was -3.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.98B) has a higher market cap than CLDX($1.35B). CLDX YTD gains are higher at: -21.053 vs. DNLI (-32.974). CLDX has higher annual earnings (EBITDA): -213.94M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. CLDX (673M). CLDX has less debt than DNLI: CLDX (3.43M) vs DNLI (48.6M). CLDX has higher revenues than DNLI: CLDX (7.56M) vs DNLI (0).
CLDXDNLICLDX / DNLI
Capitalization1.35B1.98B68%
EBITDA-213.94M-505.16M42%
Gain YTD-21.053-32.97464%
P/E RatioN/AN/A-
Revenue7.56M0-
Total Cash673M818M82%
Total Debt3.43M48.6M7%
FUNDAMENTALS RATINGS
CLDX vs DNLI: Fundamental Ratings
CLDX
DNLI
OUTLOOK RATING
1..100
475
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
9240
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that CLDX’s stock grew somewhat faster than DNLI’s over the last 12 months.

CLDX's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that CLDX’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for CLDX (92). This means that DNLI’s stock grew somewhat faster than CLDX’s over the last 12 months.

CLDX's Price Growth Rating (63) in the Biotechnology industry is in the same range as DNLI (64). This means that CLDX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as CLDX (100). This means that DNLI’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIIEX23.17N/A
N/A
Invesco EQV International Equity A
GRSIX10.28N/A
N/A
Brookfield Global Rnwbls & Sst Infrs I
EAALX21.61N/A
N/A
Eaton Vance Atlanta Capital Focused Gr A
MLNSX25.01N/A
N/A
Morgan Stanley Instl Glbl Concntr R6
FGKFX29.29N/A
N/A
Fidelity Growth Company K6

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
N/A
BEAM - CLDX
53%
Loosely correlated
N/A
NTLA - CLDX
50%
Loosely correlated
+2.83%
KYMR - CLDX
49%
Loosely correlated
N/A
DNLI - CLDX
49%
Loosely correlated
-0.22%
RVMD - CLDX
49%
Loosely correlated
+0.15%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.22%
NRIX - DNLI
57%
Loosely correlated
+2.15%
BEAM - DNLI
56%
Loosely correlated
N/A
NTLA - DNLI
55%
Loosely correlated
+2.83%
RGNX - DNLI
55%
Loosely correlated
N/A
ARWR - DNLI
54%
Loosely correlated
N/A
More